Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.77 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.76 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.76 |
| ▸ | ABL2 | P42684 | 2/20 | 0.76 |
| ▸ | RET | P07949 | 2/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | JAK2 | O60674 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | FYN | P06241 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | CSF1R | P07333 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24122640 | 0.87 | ABL1 (1.00) | ABL1DDR1DDR2ABL2RET | |
| SCHEMBL30011304 | 0.87 | ABL1 (1.00) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL589260 | 0.86 | ABL1 (1.00) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL29353054 | 0.86 | ABL1 (1.00) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL29373892 | 0.86 | ABL1 (1.00) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL29889039 | 0.86 | ABL1 (1.00) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL15798559 | 0.85 | ABL1 (0.99) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL16797824 | 0.85 | ABL1 (0.99) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL29495098 | 0.85 | ABL1 (0.99) | ABL1DDR1DDR2ABL2RET | |
| Ponatinib SCHEMBL29528953 | 0.85 | ABL1 (0.99) | ABL1DDR1DDR2ABL2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951103-B2 | Pharmaceutical composition | KYOWA KIRIN CO., LTD. (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20210077481-A1 | PHARMACEUTICAL COMPOSITION | KYOWA KIRIN CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077481-A1 | PHARMACEUTICAL COMPOSITION | EGFR, VEGFA, KDR | ABL1 514/4885DDR1 256/4885DDR2 1310/4885 |
| US-11951103-B2 | Pharmaceutical composition | EGFR, VEGFA, KDR | ABL1 514/4885DDR1 256/4885DDR2 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.